ASCO Immunotherapy Alert: BioMedTracker’s Top Abstract Picks
With cancer checkpoint inhibitors extremely high on the radar at the upcoming American Society of Clinical Oncology annual meeting, BioMedTracker analysts identify the most compelling immunotherapy abstracts.
You may also be interested in...
Clean safety profile for combination of IDO inhibitors with anti-PD-1 agents in early studies presented at the American Association for Cancer Research meeting contrasts with the toxicity-laden CTLA-4/PD-1 regimen in Bristol's Phase III CheckMate 067 study.
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.